Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Early-life environmental exposures linked to multiple health outcomes into adolescence

13

Nov 2026

Early-life environmental exposures linked to multiple health outcomes into adolescence

Environmental exposures during pregnancy and childhood can be associated with multiple aspects of health at the same time, with many of these associations persisting into adolescence health, according to a new study led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by the "la Caixa" Foundation, and in collaboration with the French National Institute for Health and Medical Research (Inserm).

Early-life environmental exposures linked to multiple health outcomes into adolescence

13

Nov 2026

Early-life environmental exposures linked to multiple health outcomes into adolescence

Environmental exposures during pregnancy and childhood can be associated with multiple aspects of health at the same time, with many of these associations persisting into adolescence health, according to a new study led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by the "la Caixa" Foundation, and in collaboration with the French National Institute for Health and Medical Research (Inserm).

Andelyn partners with Celliaz to advance gene therapy for retinitis pigmentosa

13

Nov 2026

Andelyn partners with Celliaz to advance gene therapy for retinitis pigmentosa

Andelyn Biosciences (Andelyn), a leading US-based patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), and Celliaz Co., Ltd., a South Korean biotechnology company developing next-generation regenerative therapeutics for retinal degenerative diseases, today announced a strategic partnership to advance CLZ002, an investigational adeno-associated virus (AAV)-based gene therapy for retinitis pigmentosa (RP).

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.